Centessa Pharmaceuticals: Buy Rating Driven by ORX750’s Promising Efficacy and Acquisition Potential

In a report released yesterday, Kostas Biliouris from BMO Capital maintained a Buy rating on Centessa Pharmaceuticals, with a price target of $35.00.

Kostas Biliouris has given his Buy rating due to a combination of factors that highlight the potential of Centessa Pharmaceuticals. The company’s lead product, ORX750, is expected to deliver best-in-class efficacy and safety in treating narcolepsy types 1 and 2 (NT1/NT2) and idiopathic hypersomnia (IH) by 2025. The anticipated performance includes a significant increase in sleep latency and a favorable safety profile, with minimal visual adverse effects compared to competitors.
Furthermore, the promising data from ORX750 positions Centessa Pharmaceuticals as an attractive acquisition target, potentially driving a substantial upside in stock value. The analyst also notes that the company’s diversified orexin agonist pipeline, led by ORX750, supports the Outperform rating, as it demonstrates strong safety and efficacy. Despite the competitive landscape, the large market size for these conditions suggests room for multiple blockbuster products, reinforcing the Buy recommendation.

Biliouris covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Legend Biotech, and Centessa Pharmaceuticals. According to TipRanks, Biliouris has an average return of -7.5% and a 37.35% success rate on recommended stocks.

In another report released yesterday, Needham also maintained a Buy rating on the stock with a $35.00 price target.